After chemotherapy disease progresses in some of the patients with advanced BRAF V600E mutant non-small cell lung cancer. The BRAF inhibitor dabrafenib was found to have significant anti-tumour activity in such patients. Phase II data presented at the ESMO 2014 Congress in Madrid, Spain revealed the results. "Reports of lung cancers bearing mutations in BRAF have generated considerable interest because these mutations may be associated with increased sensitivity ...
Read MoreYou have just read an article categorized health
titled Targeted Approaches to Certain Lung Cancer Show Promising Results.
Written by:
editor - Tuesday, September 30, 2014
There are currently no comments for "Targeted Approaches to Certain Lung Cancer Show Promising Results"
Post a Comment